

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

WILLIAMS et al.

Atty. Ref.: 550-453

Serial No. Div. of Serial No. 09/291,038

Group: Unassigned

Filed: July 18, 2003

Examiner: Unassigned

For: EOTAXIN: EOSINOPHIL CHEMOTACTIC CYTOKINE

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

July 18, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449, copies of each identified document has been submitted and made of record in the parent application Serial No. 09/291,038. Further copies of the cited documents are not believed to be required however the office is


requested to advise the undersigned if otherwise.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

· WILLIAMS et al.
· Div. of Serial No. 09/291,038

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: 
B. J. Sadoff
Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

550-453

Div. of 09/291,038

Applicant

WILLIAMS et al.

Filing Date

Group

July 18, 2003

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,514,555	5/1996	SPRINGER et al.			
	5,079,228	1/1992	COHEN et al.			
	3,447,978	6/1969	BLUHM			
	6,403,782	6/2002	Luster			

FOREIGN PATENT DOCUMENTS

				TRANSLATION			
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
WO 95/31467	11/1995	PCT					
PCT/CA94/00528	3/1992	PCT					
WO 93/11159	3/1992	WO					
WO 95/07985	3/1995	WO					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Faccioli et al, "The accumulation of ¹¹¹ In-eosinophils induced by inflammatory mediators, <i>in vivo</i> ", Immunology 73:222-227 (1991)
	Weg et al, "A Monoclonal Antibody Recognizing Very Late Activation Antigen-4 Inhibits Eosinophil Accumulation In Vivo", J. Exp. Med. 177:561-566 (1993)
	Dahinden et al, "Monocyte Chemotactic Protein 3 Is a Most Effective Basophil- and Eosinophil-activating Chemokine", J. Exp. Med. 179:751-756 (1994)
	Van Damme et al, "Structural and Functional Identification of Two Human, Tumor-derived Monocyte Chemotactic Proteins (MCP-2 and MCP-3) Belonging to the Chemokine Family", J. Exp. Med. 176:59-65 (1992)
	Opdenakker et al, "Human monocyte chemotactic protein-3 (MCP-3): molecular cloning of the cDNA and comparison with other chemokines", Biochemical and Biophysical Research Communications 191(2):535-542 (1993)
	Yoshimura et al, FEBS LETTERS 244 (2) Feb 1989, 487-493
	Jose et al., "Eotaxin: A potent Eosinophil Chemoattractant Cytokine detected in a guinea pig model of allergic airways inflammation", The Journal of Experimental Medicine, Vol 179, 1 March 1994, pp. 881-887
	Griffith-Johnson et al. "The Chemokine, Eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation in the lung in vivo", Biochem. and Biophys. Res. Comm., Vol 197, No. 3, 12/3/93, pp. 1167-1172
	Colins et al., "Eosinophil accumulation induced by human interleukin-8 in the guinea pig in vivo", Immunology, Vol. 79, No. 2, June 1993, pp. 312-318
	Isoda, "Eosinophil Chemotactic activity of beta-galactosidase", Biological Abstracts, Vol. 84, No. 9, 1987, Abstract No. 87994, p. AB-544
	FEBS LETTERS 244 (2) Tokyo pages 137-140
	Kameyoshi et al., "Cytokine RANTES release by Thrombin-stimulated platelets is a potent attractant for human eosinophils", The Journal of Experimental Medicine, Vol. 176, No. 2, 8/1/92, pp. 587-592
	Rot et al., "RANTES and macrophage inflammatory protein-1 alpha induce the migration and activation of normal human eosinophil granulocytes", The Journal of Experimental Medicine, Vol 176, No. 6, 12/1/92, pp. 1489-1495
	Kuna et al. "RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils", Chemical Abstracts, Vol. 117, No. 11, 9/14/92, Abstract No. 109899k, p. 705, column L
	Lellouch-Tubiane et al., "Eosinophil recruitment into guinea pig lungs after PAF-acether and Allergen administration", American Review of Respiratory Disease, Vol. 137, No. 4, 4/4/88, pp. 948-954
	Humbles et al. "Kinetics of Eotaxin Generation and Its Relationship to Eosinophil...", J. Exp. Med. Vol 186, No. 4, 8/18/97, pp 601-612
	Sanz et al., "Human Eotaxin Induces α_4 and β_2 Integrin-Dependent Eosinophil..." J. Immunol. 160: 3569-3576, (1998)
	Sabroe et al. "Cloning and Characterization of the Guinea Pig Eosinophil...", J. Immunol 161:6139-6147

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

550-453**Div. of 09/291,038**

Applicant

WILLIAMS et al.

Filing Date

Group

July 18, 2003**Unassign d**

	OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)
	Sabroe et al. "Differential Regulation of Eosinophil Chemokine Signaling..." J. Immunol. 162:2946-2955
	Kohler & Milstein Ref. Continuous cultures of fused cells..." Nature, Vol 256, August 7, 1975
	Tiexeira et al., "Chemokine-induced Eosinophil Recruitment", J. Clin. Invest. Vol. 100, No. 7, Oct. 1997, pp 1657-1666
	Kohler & Milstein Ref. Continuous cultures of fused cells..." Nature, Vol 256, August 7, 1975
	Bowie et al., Science Vol. 247 (March 16, 1990) pp. 1306-1310
	Ponath, et al., Journal of Clinical Investigation, Vol. 97, No. 3, February 1996, pp. 604-612
	Jose et al., Biochemical and Biophysical Research Communication Vol. 205, No. 1 (1994), November 30, 1994, pp. 780-794
	Cummingham et al., Science Vol. 222 (June 2, 1989) pp. 1081-1085
	Schlesinger, D. H., Macromolecular Sequencing and Synthesis (Ed. Schlesinger, D.H.) Alan R. Liss, Inc., (1988) pp. 127-149
	Reeck et al., Cell, Vol. 50, 667 (August 28, 1987) Letter to the Editor
	Marleau et al., The Journal of Immunology 1996, 157:4141-4146
	Heath et al., Journal of Clinical Investigation, Vol. 99, No. 2, January 1997, pp 178-184
	Kitaura et al., JBC (1996) 271, pp. 7725-7730
	Rothenberg et al., PNAS (1995) 92, pp. 8960-8964
	Coffman et al, Science, Vol. 245, pages 308-310
	Mikayama et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pages 10056-10060
	Voet et al., Biochemistry, John Wiley & Sons, Inc., pages 126-128 and 228-234

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.